ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial

Non-alcoholic fatty liver disease is a growing health burden with limited treatment options worldwide. Herein we report a randomized, double-blind, placebo-controlled, multiple-dose trial of a first-in-class pan-phosphodiesterase inhibitor ZSP1601 in 36 NAFLD patients (NCT04140123). There were three...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yue, Li, Haijun, Zhang, Hong, Chen, Xiaoxin, Chen, Jinjun, Xu, Zhongyuan, You, Hong, Dong, Ruihua, Peng, Yun, Li, Jing, Li, Xiaojiao, Wu, Dandan, Zhang, Lei, Cao, Di, Jin, He, Qiu, Dongdong, Yang, Aruhan, Lou, Jinfeng, Zhu, Xiaoxue, Niu, Junqi, Ding, Yanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570369/
https://www.ncbi.nlm.nih.gov/pubmed/37828034
http://dx.doi.org/10.1038/s41467-023-42162-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570369/
https://www.ncbi.nlm.nih.gov/pubmed/37828034
http://dx.doi.org/10.1038/s41467-023-42162-0

Ejemplares similares